Treatment with chloroquine sulphate or chloroquine phosphate or hydroxychloroquine

Cardiomyopathy - Treatment with chloroquine sulphate or chloroquine phosphate or hydroxychloroquine Factor

Last reviewed for CCPS 18 July 2007.

Preliminary questions [38034]

38035 there is some evidence that being treated daily with chloroquine sulphate, chloroquine phosphate or hydroxychloroquine may be a factor in the development or worsening of the condition under consideration.

38534 the veteran has been treated daily with chloroquine sulphate, chloroquine phosphate or hydroxychloroquine at some time.

38036 the veteran has been treated daily with chloroquine sulphate, chloroquine phosphate or hydroxychloroquine for at least one year at some time.

38039the veteran has established the causal connection between being treated daily with chloroquine sulphate, chloroquine phosphate or hydroxychloroquine and VEA service for the condition under consideration.

38040the veteran has established the causal connection between being treated daily with chloroquine sulphate, chloroquine phosphate or hydroxychloroquine and VEA service for the clinical onset of the condition under consideration.

38042the veteran has established the causal connection between being treated daily with chloroquine sulphate, chloroquine phosphate or hydroxychloroquine and operational service for the clinical onset of the condition under consideration.

or

38043the veteran has established the causal connection between being treated daily with chloroquine sulphate, chloroquine phosphate or hydroxychloroquine and eligible service for the clinical onset of the condition under consideration.

or

7334

the clinical onset of the condition under consideration occurred after the end of the veteran's last period of VEA service.

7335

the condition under consideration permanently worsened.

38041the veteran has established the causal connection between being treated daily with chloroquine sulphate, chloroquine phosphate or hydroxychloroquine and VEA service for the clinical worsening of the condition under consideration.

38044the veteran has established the causal connection between being treated daily with chloroquine sulphate, chloroquine phosphate or hydroxychloroquine and operational service for the clinical worsening of the condition under consideration.

or

38045the veteran has established the causal connection between being treated daily with chloroquine sulphate, chloroquine phosphate or hydroxychloroquine and eligible service for the clinical worsening of the condition under consideration.

Clinical onset and operational service [38042]

38046

the veteran was treated daily with chloroquine sulphate, chloroquine phosphate or hydroxychloroquine for at least the one year before the clinical onset of the condition under consideration.

38047

operational service made a material contribution to the veteran being treated daily with chloroquine sulphate, chloroquine phosphate or hydroxychloroquine for at least the one year before the clinical onset of the condition under consideration.

or

38057

the veteran being treated daily with chloroquine sulphate, chloroquine phosphate or hydroxychloroquine for at least one year was materially contributed to by treatment of an illness or injury which is identifiable.

38058

the identified illness or injury made a material contribution to the veteran being treated daily with chloroquine sulphate, chloroquine phosphate or hydroxychloroquine for at least the one year before the clinical onset of the condition under consideration.

38061the identified illness or injury which made a material contribution to the veteran being treated daily with chloroquine sulphate, chloroquine phosphate or hydroxychloroquine for at least one year is causally related to operational service.

Clinical onset and eligible service [38043]

38048

the veteran has been treated daily with chloroquine sulphate, chloroquine phosphate or hydroxychloroquine for at least two years at some time.

38049

the veteran was treated daily with chloroquine sulphate, chloroquine phosphate or hydroxychloroquine for at least the two years before the clinical onset of the condition under consideration.

38050

eligible service made a material contribution to the veteran being treated daily with chloroquine sulphate, chloroquine phosphate or hydroxychloroquine for at least the two years before the clinical onset of the condition under consideration.

or

38057

the veteran being treated daily with chloroquine sulphate, chloroquine phosphate or hydroxychloroquine for at least one year was materially contributed to by treatment of an illness or injury which is identifiable.

38059

the identified illness or injury made a material contribution to the veteran being treated daily with chloroquine sulphate, chloroquine phosphate or hydroxychloroquine for at least two years.

38060

the identified illness or injury made a material contribution to the veteran being treated daily with chloroquine sulphate, chloroquine phosphate or hydroxychloroquine for at least the two years before the clinical onset of the condition under consideration.

38062the identified illness or injury which made a material contribution to the veteran being treated daily with chloroquine sulphate, chloroquine phosphate or hydroxychloroquine for at least two years is causally related to eligible service.

Clinical worsening and operational service [38044]

38051

the veteran was treated daily with chloroquine sulphate, chloroquine phosphate or hydroxychloroquine after the clinical onset of cardiomyopathy and for at least the one year before the clinical worsening of the condition under consideration.

38052

operational service made a material contribution to the veteran being treated daily with chloroquine sulphate, chloroquine phosphate or hydroxychloroquine after the clinical onset of cardiomyopathy and for at least the one year before the clinical worsening of the condition under consideration.

or

38057

the veteran being treated daily with chloroquine sulphate, chloroquine phosphate or hydroxychloroquine for at least one year was materially contributed to by treatment of an illness or injury which is identifiable.

38063

the identified illness or injury made a material contribution to the veteran being treated daily with chloroquine sulphate, chloroquine phosphate or hydroxychloroquine after the clinical onset of cardiomyopathy and for at least the one year before the clinical worsening of the condition under consideration.

38061the identified illness or injury which made a material contribution to the veteran being treated daily with chloroquine sulphate, chloroquine phosphate or hydroxychloroquine for at least one year is causally related to operational service.

38065

the clinical onset of the condition under consideration occurred prior to that part of operational service to which the identified illness or injury, which made a material contribution to the veteran being treated daily with chloroquine sulphate, chloroquine phosphate or hydroxychloroquine for at least one year, is causally related.

Clinical worsening and eligible service [38045]

38048

the veteran has been treated daily with chloroquine sulphate, chloroquine phosphate or hydroxychloroquine for at least two years at some time.

38054

the veteran was treated daily with chloroquine sulphate, chloroquine phosphate or hydroxychloroquine after the clinical onset of cardiomyopathy and for at least the two years before the clinical worsening of the condition under consideration.

38055

eligible service made a material contribution to the veteran being treated daily with chloroquine sulphate, chloroquine phosphate or hydroxychloroquine after the clinical onset of cardiomyopathy and for at least the two years before the clinical worsening of the condition under consideration.

or

38057

the veteran being treated daily with chloroquine sulphate, chloroquine phosphate or hydroxychloroquine for at least one year was materially contributed to by treatment of an illness or injury which is identifiable.

38059

the identified illness or injury made a material contribution to the veteran being treated daily with chloroquine sulphate, chloroquine phosphate or hydroxychloroquine for at least two years.

38064

the identified illness or injury made a material contribution to the veteran being treated daily with chloroquine sulphate, chloroquine phosphate or hydroxychloroquine after the clinical onset of cardiomyopathy and for at least the two years before the clinical worsening of the condition under consideration.

38062the identified illness or injury which made a material contribution to the veteran being treated daily with chloroquine sulphate, chloroquine phosphate or hydroxychloroquine for at least two years is causally related to eligible service.

38066

the clinical onset of the condition under consideration occurred prior to that part of eligible service to which the identified illness or injury, which made a material contribution to the veteran being treated daily with chloroquine sulphate, chloroquine phosphate or hydroxychloroquine for at least two years, is causally related.

Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/c-d/cardiomyopathy-g021-4254-425964866748/rulebase-cardiomyopathy/treatment-chloroquine-sulphate-or-chloroquine-phosphate-or-hydroxychloroquine